Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
University of California, San Francisco
OHSU Knight Cancer Institute
University Hospital, Ghent
Hoffmann-La Roche
CSPC Ouyi Pharmaceutical Co., Ltd.
Memorial Sloan Kettering Cancer Center
Columbia University
EpiAxis Therapeutics
Celgene
The Methodist Hospital Research Institute
University of Chicago
Incyte Corporation
University of Utah
University of California, San Francisco
Celgene Corporation